Cost-effectiveness Study of Antidiabetic Drugs in Type 2 Diabetes Mellitus Patients From Mumbai, India
- Diabetes is fast gaining the status of a potential epidemic in India, with >62 million individuals currently diagnosed with the disease.1 India currently faces an uncertain future in relation to the potential burden that diabetes may impose on the country. An estimated US$ 2.2 billion would be needed to sufficiently treat all cases of type 2 diabetes mellitus (T2DM) in India.2 Many interventions can reduce the burden of this disease. However, health care resources are limited; thus, interventions for diabetes treatment should be prioritized.
| Author: | Dnyanesh LimayeORCiDGND, K. Todi, J. Shroff, A. Ramaswamy, P. Kulkarni, Vaidehi Limaye, Gerhard FortwengelORCiDGND |
|---|---|
| URN: | urn:nbn:de:bsz:960-opus4-9151 |
| DOI: | https://doi.org/10.1016/j.curtheres.2016.05.006 |
| Parent Title (English): | Current Therapeutic Research |
| Document Type: | Article |
| Language: | English |
| Release Date: | 2016/07/14 |
| Tag: | India; antidiabetic; cost-effectiveness; diabetes mellitus |
| Volume: | 78 |
| Issue: | Supplement |
| First Page: | S2 |
| Last Page: | S3 |
| Link to catalogue: | 1684942969 |
| Institutes: | Fakultät III - Medien, Information und Design |
| DDC classes: | 610 Medizin, Gesundheit |
| Licence (German): |  Creative Commons - CC BY-NC-ND - Namensnennung - Nicht kommerziell - Keine Bearbeitungen 4.0 International |
